BioLineRx to Participate in the 12th Annual LifeSci Partners Corporate Access Event

Rhea-AI Summary

BioLineRx Ltd. (NASDAQ: BLRX) announced its participation in the 12th Annual LifeSci Partners Corporate Access Event occurring from January 9-11, 2023, in San Francisco, CA. Management will be available for one-on-one meetings on January 11, 2023. BioLineRx focuses on oncology, with its lead drug, motixafortide, showing promise in multiple studies, including a Phase 3 trial for multiple myeloma and a Phase 2a trial for pancreatic cancer. The FDA has accepted its NDA submission with a PDUFA date of September 9, 2023.

TEL AVIV, Israel, Nov. 28, 2022 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today announced that management will participate in the 12^th Annual LifeSci Partners Corporate Access Event, taking place January 9-11, 2023, in San Francisco, CA, and will be available for one-one-one meetings on January 11, 2023. Learn more about the event and schedule an in-person meeting with BioLineRx management here.

About BioLineRx

BioLineRx Ltd. (NASDAQ/TASE: BLRX) is a pre-commercial-stage biopharmaceutical company focused on oncology. The Company's lead development program, motixafortide, a novel selective inhibitor of the CXCR4 chemokine receptor, may support diverse therapeutic approaches in oncology and other diseases.  APHEXDA® (motixafortide) was successfully evaluated in a Phase 3 study in stem cell mobilization for autologous transplantation in multiple myeloma patients, has reported positive results from a pre-planned pharmacoeconomic study in the U.S., and has had its NDA submission accepted by the FDA with a PDUFA date of September 9, 2023. Motixafortide was also successfully evaluated in a Phase 2a study for the treatment of pancreatic cancer (PDAC) in combination with KEYTRUDA® and chemotherapy and is currently being studied in combination with LIBTAYO® and chemotherapy as a first-line PDAC therapy. A randomized phase 2b study with 200 patients in combination with an anti-PD1 and chemotherapy as a first-line PDAC therapy will initiate in 2023. BioLineRx is also developing a second oncology program, AGI-134, an immunotherapy treatment for multiple solid tumors that is currently being investigated in a Phase 1/2a study. For additional information on BioLineRx, please visit the Company's website at www.biolinerx.com, where you can review the Company's SEC filings, press releases, announcements, and events.

Contacts:

United States
John Lacey
BioLineRx
+1-781-392-5514
IR@biolinerx.com

Tim McCarthy
LifeSci Advisors, LLC
tim@lifesciadvisors.com

Israel
Moran Meir
LifeSci Advisors, LLC
+972-54-476-4945
moran@lifesciadvisors.com

View original content:https://www.prnewswire.com/news-releases/biolinerx-to-participate-in-the-12th-annual-lifesci-partners-corporate-access-event-301688220.html

SOURCE BioLineRx Ltd.

FAQ

What event will BioLineRx participate in January 2023?

BioLineRx will participate in the 12th Annual LifeSci Partners Corporate Access Event from January 9-11, 2023.

When will BioLineRx management hold one-on-one meetings?

BioLineRx management will hold one-on-one meetings on January 11, 2023.

What is the focus of BioLineRx?

BioLineRx is a pre-commercial-stage biopharmaceutical company focused on oncology.

What significant drug is BioLineRx developing?

BioLineRx is developing motixafortide, which is being studied for various oncology treatments.

What is the PDUFA date for BioLineRx's NDA submission?

The PDUFA date for BioLineRx's NDA submission is September 9, 2023.